by B2i | Jan 27, 2020 | Press Releases
JUPITER, FL / January 27, 2020 / Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate...
by B2i | Jan 6, 2020 | Press Releases
Expanded ZAPI Program and Positive Preliminary Results from ZAPI Animal Study New Collaboration Agreement with Top Ten Pharmaceutical Company Expanded Research Relationship with Leading Pharmaceutical Company IIBR Collaboration Achieved Expression of Fc-fusion Enzyme...
by B2i | Nov 25, 2019 | Press Releases
High G0 Glycosylation Level Driving Program Acceleration JUPITER, FL / November 25, 2019 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression...
